# A Study of DCC-2701 in Participants With Advanced Solid Tumors

> **NCT02228811** · PHASE1 · TERMINATED · sponsor: **Deciphera Pharmaceuticals, LLC** · enrollment: 44 (actual)

## Conditions studied

- Locally Advanced Tumors
- Metastatic Solid Tumors
- Cancers With MET Genomic Alterations
- Cancers With TRK Genomic Alterations

## Interventions

- **DRUG:** DCC-2701 tablet

## Key facts

- **NCT ID:** NCT02228811
- **Lead sponsor:** Deciphera Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2017-11
- **Final completion:** 2018-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2018-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02228811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02228811, "A Study of DCC-2701 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02228811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*